{"id":"e5e6729671c0","type":"article","url":"https://hartvaat.nl/2016/09/27/2016-acc-aha-hfsa-gerichte-update-nieuwe-farmacologische-hartfalentherapie/","title":"2016 ACC/AHA/HFSA gerichte update: nieuwe farmacologische hartfalentherapie","title_en":"2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["acuut-hartfalen","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2016.05.011","source_url":"https://doi.org/10.1016/j.jacc.2016.05.011","authors":["Clyde W Yancy","Mariell Jessup","Biykem Bozkurt","Javed Butler","Donald E Casey","Monica M Colvin","Mark H Drazner","Gerasimos Filippatos","Gregg C Fonarow","Michael M Givertz","Steven M Hollenberg","JoAnn Lindenfeld","Frederick A Masoudi","Patrick E McBride","Pamela N Peterson","Lynne Warner Stevenson","Cheryl Westlake"],"significance":9,"published":"2016-09-27","source_date":"2016-09-27","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/esc-richtlijn-hartfalen-2021/","https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"The 2016 ACC/AHA/HFSA focused update introduced new recommendations for pharmacological heart failure therapy, most notably endorsing sacubitril-valsartan (ARNI) for HFrEF based on the PARADIGM-HF results. This update marked the entry of neprilysin inhibition into guideline-directed heart failure treatment.","created":"2026-07-03T10:26:19Z","updated":"2026-07-03T18:38:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerichte richtlijnupdate met nieuwe aanbevelingen voor farmacologische hartfalentherapie, waaronder sacubitril/valsartan (ARNI). Integratie van PARADIGM-HF-resultaten in de praktijkrichtlijnen.","abstract_original":""}